Nolpaza tablets gastro-resistant

Country: Арменија

Језик: Енглески

Извор: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активни састојак:

pantoprazole (pantoprazole sodium sesquihydrate)

Доступно од:

KRKA d.d.

АТЦ код:

A02BC02

INN (Међународно име):

pantoprazole (pantoprazole sodium sesquihydrate)

Дозирање:

20mg

Фармацеутски облик:

tablets gastro-resistant

Јединице у пакету:

(28/2x14/) in blister, (56/4x14/) in blister

Тип рецептора:

Prescription

Статус ауторизације:

Registered

Датум одобрења:

2021-04-16

Карактеристике производа

                                PI_Text001952_1
– Updated:
Page 1 of 11
1.
NAME OF THE MEDICINAL PRODUCT
Nolpaza
®
20 mg gastro-resistant tablets
Nolpaza
®
40 mg gastro-resistant tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 20 mg gastro-resistant tablet contains 20 mg pantoprazole as
22.55 mg pantoprazole sodium
sesquihydrate.
Each 40 mg gastro-resistant tablet contains 40 mg pantoprazole as
45.10 mg pantoprazole sodium
sesquihydrate.
Excipient:
Each 20 mg gastro-resistant tablet contains 18 mg sorbitol (E420).
Each 40 mg gastro-resistant tablet contains 36 mg sorbitol (E420).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant tablet
Light yellowish brown, oval, slightly biconvex film-coated tablets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_Adults and adolescents 12 years of age and above_
-
Symptomatic gastro-oesophageal reflux disease.
-
For long-term management and prevention of relapse in reflux
oesophagitis.
-
Reflux oesophagitis
_Adults_
-
Prevention of gastroduodenal ulcers induced by non-selective
non-steroidal anti-inflammatory
drugs (NSAIDs) in patients at high risk with a need for continuous
NSAID treatment (see
section 4.4).
-
Eradication of _Helicobacter pylori _(_H. pylori_) in combination with
appropriate antibiotic therapy
in patients with _H. pylori _associated ulcers.
-
Gastric and duodenal ulcers.
-
Zollinger-Ellison syndrome and other pathological hypersecretory
conditions.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The tablets should not be chewed or crushed, and should be swallowed
whole 1 hour before a meal
with some water.
_RECOMMENDED DOSE_
_ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND ABOVE_
CONFIDENTIAL
Nolpaza gastro-resistant tablets 20 mg, 40 mg
VOL: 1; P: 30 / 64
PI_Text001952_1
– Updated:
Page 2 of 11
Symptomatic gastro-oesophageal reflux disease
The recommended oral dose is one Nolpaza 20 mg gastro-resistant tablet
per day. Symptom relief is
generally accomplished within 2–4 weeks. If this is not sufficient,
symptom relief will normally be
achieve
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Руски 16-04-2021

Обавештења о претрази у вези са овим производом

Погледајте историју докумената